ESGCT preclinical roundup; plus Generation, Pionyr and more

Preclinical data from companies presenting at the European Society of Gene and Cell Therapy (ESGCT) 2021 Virtual Congress highlight a range of gene editing strategies and delivery modalities nearing the clinic.

Beam Therapeutics Inc. (NASDAQ:BEAM) showed its lipid nanoparticle (LNP)-delivered base editing therapy corrected R83C in G6PC, one of the primary disease-causing mutations of glycogen storage disorder 1a, and prevented growth impairment and metabolic defects in diseased mice...